Ionis Pharmaceuticals Inc IONS Financial and Strategic SWOT Analysis Review [Report Updated: 13062018] Prices from USD $125

15:45 EDT 11 Aug 2018 | BioPortfolio Report Blog

Ionis Pharmaceuticals Inc IONS Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Ionis Pharmaceuticals Inc Ionis formerly ISIS Pharmaceuticals, Inc. focuses on the discovery and development of RNAtargeted drugs. The company develops first inclass medicines for the treatment of cardiovascular and metabolic disorders, cancer and rare diseases. Ionis develops its products based on its proprietary antisense technology. Its lead product candidates in Phase III development include Kynamro injection being developed in collaboration with Genzyme for the reduction of lowdensity lipoprotein cholesterol in patients suffering from homozygous familial hypercholesterolemia, or HoFH; Volanesorsen being developed for the treatment of rare, genetic disorders marked by severely high triglyceride levels; IONISTTRRx, a firstinclass drug for the treatment of all forms of TTR amyloidosis and Nusinersen being developed for the spinal muscular atrophy SMA. Ionis is headquartered in Carlsbad, California, the US.

Ionis Pharmaceuticals Inc Key Recent Developments

May 04,2018 Ionis Announces First Quarter 2018 Financial Results

Apr 17,2018 Presentations at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases

Feb 27,2018 Ionis Announces Fourth Quarter and Full Year 2017 Financial Results

Nov 07,2017 Ionis Announces Management Transitions

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Ionis Pharmaceuticals Inc IONS Financial and Strategic SWOT Analysis Review [Report Updated: 13062018] Prices from USD $125


More From BioPortfolio on "Ionis Pharmaceuticals Inc IONS Financial and Strategic SWOT Analysis Review [Report Updated: 13062018] Prices from USD $125"

Quick Search


Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...